stockrow
Wednesday 11 November 2026
Export REPL’s income statement to Excel — free account
Replimune Group, Inc.
REPL- EPS
- +39.7%
- Free cash flow
- +42.2%
- Total debt
- +74.3%
Quarter to September 2026, against a year earlier
21.88
1.40
−6.01%
Follow REPL
Alert me
Replimune Group, Inc. (REPL) Debt to equity
Replimune Group, Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 0.6×, down 0.0× from fiscal 2026 (0.6×). Over the past ten years it has ranged from 0.0× (fiscal 2018) to 0.6× (fiscal 2026) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2026 | 0.6× | 280.99% |
| FY2025 | 0.2× | (8.78%) |
| FY2024 | 0.2× | 92.40% |
| FY2023 | 0.1× | 59.70% |
| FY2022 | 0.1× | 19.56% |
| FY2021 | 0.0× | (73.78%) |
| FY2020 | 0.2× | 297.48% |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | 0.6× | (40.90%) |
| Jun 2026 | 1.0× | 58.16% |
| Mar 2026 | 0.6× | 91.13% |
| Dec 2025 | 0.3× | 25.44% |
| 35 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.6×
Ten-year median
0.1×
Current reading's percentile
100
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.0× |
| ZYME Zymeworks Inc. compare | 0.0× |
| VIR Vir Biotechnology, Inc. compare | 0.0× |
| IMNM Immunome, Inc. compare | 0.0× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 0.0× |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.0× |
| AUPH Aurinia Pharmaceuticals Inc compare | 0.1× |
| VERA Vera Therapeutics, Inc. compare | 0.2× |
| REPL Replimune Group, Inc. | 0.6× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.2× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)